Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 10/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | AHR | P35869 | 1/20 | 0.54 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.49 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15299992 | 0.86 | AHR (0.54) | GAAPKMAHRSMYD3TDP1 | |
| SCHEMBL14089190 | 0.85 | PKM (0.60) | PKMIDO1 | |
| SCHEMBL6602558 | 0.83 | GAA (0.57) | GAAPKMAHRSMYD3IDO1 | |
| SCHEMBL2203244 | 0.83 | GAA (0.64) | GAAPKMAHRSMYD3IDO1 | |
| SCHEMBL689168 | 0.83 | GAA (0.60) | GAAPKMAHRSMYD3IDO1 | |
| SCHEMBL10293161 | 0.83 | GAA (0.60) | GAAPKMAHRSMYD3IDO1 | |
| SCHEMBL517067 | 0.83 | GAA (0.60) | GAAPKMAHRSMYD3IDO1 | |
| SCHEMBL689118 | 0.82 | PKM (0.64) | GAAPKMAHRSMYD3IDO1 | |
| SCHEMBL689464 | 0.82 | GAA (0.56) | GAAPKMAHRSMYD3IDO1 | |
| SCHEMBL12431627 | 0.82 | GAA (0.56) | GAAPKMAHRSMYD3IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140205537-A1 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140205537-A1 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140205537-A1 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8344018-B2 | Oxindolyl inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| WO-2012178015-A2 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012178015-A2 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| US-20110135594-A1 | OXINDOLYL INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2011-06-09 | — | — | US | disclosed |
| EP-2303841-A1 | OXINDOLYL INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-06 | — | — | EP | disclosed |
| US-7714146-B2 | Azulene-oxindole compounds as multiple-kinase inhibitors and useful as anticancer agents | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2010-05-11 | — | — | US | disclosed |
| WO-2010009166-A1 | OXINDOLYL INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20080194629-A1 | 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors | BAESCHLIN DANIEL KASPAR | 2008-08-14 | — | — | US | disclosed |
| US-20080125590-A1 | Azulene compounds | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2008-05-29 | — | — | US | disclosed |
| EP-1918277-A2 | Azulene compounds | Industrial Technology Research Institute (TW) | 2008-05-07 | — | — | EP | disclosed |
| US-20050032871-A1 | Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors | SUGEN, INC. | 2005-02-10 | — | — | US | disclosed |
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | SUGEN, INC. | 2004-09-23 | — | — | US | disclosed |
| EP-0912557-B1 | OXINDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-07-09 | — | — | EP | disclosed |
| US-6265411-B1 | ANGIOGENESIS INHIBITOR | ZENECA LIMITED (GB) | 2001-07-24 | — | — | US | disclosed |
| EP-0912557-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997042187-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1997-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140205537-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, MAP2 | GAA 872/4885PKM 1039/4885AHR 4284/4885 |
| US-20050032871-A1 | Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors | MAP3K20, CDK20, STK10 | GAA 1297/4885PKM 283/4885AHR 2417/4885 |
| US-20080125590-A1 | Azulene compounds | AZI2, PRMT5, BRCA1 | GAA 2704/4885PKM 4208/4885AHR 1545/4885 |
| US-20080194629-A1 | 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors | REN, ACE, AGTR1 | GAA 139/4885PKM 1191/4885AHR 3443/4885 |
| US-20110135594-A1 | OXINDOLYL INHIBITOR COMPOUNDS | HDAC1, HDAC8, HDAC11 | GAA 510/4885PKM 443/4885AHR 1800/4885 |
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | MAP3K15, MAP3K20, MAP3K19 | GAA 3834/4885PKM 951/4885AHR 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.